Cancer
22 Results were found on Technologies
Sub Category Name
Noncoding RNA-Based Strategy for Diagnosis and Monitoring of Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC) is one of the deadliest forms of cancer, with a five-year survival rate of less than 10%. A major contributor to this high mortality is the lack of effective tools for early detection — the disease is typically diagnosed at an advanced, often inoperable stage. Current diagnostic approaches, including imaging and […] Read More >
Assessing Neu5Gc Disease Risk: A Novel Diagnostic and Dietary Management Tool
Our technology identifies individuals at increased risk of developing diseases related to Neu5Gc consumption. By analyzing antibody repertoire scores and Neu5Gc intake, the method predicts disease likelihood and provides tailored dietary recommendations to reduce risk. Unmet Need Neu5Gc, a non-human sialic acid present in red meat and dairy, has been implicated in chronic inflammatory conditions […] Read More >
Diagnostic Tool for Assessing Breast Cancer Aggressiveness via Neutrophil-Tumor Cell Interactions
A novel diagnostic approach based on the discovery that neutrophils physically interact with tumor cells in breast cancer, creating a unique signaling niche that enhances cancer aggressiveness. This interaction can be used to assess the aggressiveness of breast cancer, offering a new way to predict patient outcomes and guide treatment strategies. Unmet Need Current diagnostic […] Read More >
Therapeutic Targeting of CD45: A Novel Approach to Overcome Immunotherapy Resistance
Revolutionizing Cancer Immunotherapy While immune checkpoint inhibitors have transformed cancer treatment, only 50% of patients fail to respond, with resistance being a major challenge, particularly in aggressive cancers such as triple-negative breast cancer (TNBC). TNBC accounts for 15–20% of breast cancer cases and is often diagnosed at advanced stages, with current therapies offering limited efficacy. […] Read More >
Restoring Immunity Against GI Cancers
BACKGROUND GI cancers cause over 3.5 million deaths per year globally, accounting for 35% of all cancer-related deaths. Colorectal carcinoma (CRC) is the world’s second leading cause of cancer death. Current immunotherapy treatments for CRC are hamstrung by low response rate, acquired resistance, relapse and severe side effects. ImmuNovation presents a disruptive nanomodular technology utilizing […] Read More >
Novel Anti-Tumor Response treatment targeting ErbB receptors and Nucleolin interactions
ErbBs subfamily receptors are mediators of cell growth signals. They have long been associated with a wide variety of lung, ovarian, colon, breast, prostate, and other carcinomas. Nucleolin is a major nucleolar protein of growing eukaryotic cells and is present on the cell surface of a range of cancers. Recently, a robust oncogenic interaction between […] Read More >
Early Detection of Ovarian Cancer
We developed a novel proteomic diagnostic assay for detection of epithelial ovarian cancer, offering: • High sensitivity for early stage disease to increase the likelihood of cure. • High specificity for potential delay of risk-reducing surgical procedure. • Early ovarian cancer diagnosis for all age-groups and risk-groups (i.e., BRCA carriers). THE NEED Over 240,000 new […] Read More >
Mirna for the Treatment of Metastatic Breast Cancer
Metastasis is the primary cause for mortality in breast cancer. We showed that breast cancer metastasis can be prevented by miR-96 or miR-182 treatment. We found that miR-96/miR-182 downregulates Palladin protein levels, thereby reducing breast cancer cell migration and invasion. A hydrogel-embedded, gold-nanoparticle-based delivery vehicle provides efficient local, selective, and sustained release of miR-96/miR-182, markedly […] Read More >
Novel Human Anti-Met Monoclonal Antibodies for Cancer Immunotherapy
MET is clinically validated target in several cancer types. MET operates just downstream to the famous P53. Addiction of cancers like breast and lung to MET as well as its absence from healthy adult tissues makes it a highly desirable target. Existing anti-MET marketed drugs (crizotinib & cabozantinib) are non-specific kinase inhibitors, having high toxicity […] Read More >
Repurposing of Antibiotics for treating APC (Adenomatous Polyposis Coli) Related Colorectal Cancer
Restoration of Adenomatous Polyposis Coli (APC) gene expression by means of antibiotic erythromycin for the treatment of Familial Adenomatous Polyposis. The Technology: Treatment for APC by conventional antibiotics to regulate adenoma growth and delay the need for preventive surgery in Familial Adenomatous Polyposis (FAP) patients. The Need: FAP is a high penetrance devastating syndrome manifested […] Read More >
Macrolid Induced Correction of Premature Stop Codons: A novel Treatment for Colorectal Cancer
Restoration of premature termination codons (PTCs) caused by nonsense mutations for the treatment of Familial Adenomatous Polyposis. The Need Familial Adenomatous Polyposis (FAP) is a high penetrance devastating syndrome manifested by dozens to thousands of colonic adenomas. FAP patients require tight supervision and eventually undergo surgery, to prevent inevitable development of colorectal cancer (CRC) by […] Read More >
Therapeutic Vaccine for the Treatment of Cancer
An active cancer vaccine strategy targeting tumor-associated carbohydrate antigens expressed on tumor cells using biomimetic glyconanoparticles generated from unique red blood cells. The resulting sustained immune response inhibits tumor growth. THE NEED While envisioned already in 1891, only a few cancer vaccines have been approved by the FDA thus far. The key barriers to their […] Read More >
3D Bioprinting of Tumor Models for Personalized Drug Screening and Disease Modeling
This technology aims to provide a three-dimensional (3D) bioprinted tumor model based on natural and synthetic polymers containing several types of cells, which resembles cancer tissue. Our 3D-bioprinted tumor model has potential to predict the clinical outcome of a treatment compared to the other existing solutions, which either rely solely on genetic profiling or do […] Read More >
Novel Ionizable Lipids for Delivery of Nucleic Acids (mRNA, DNA, siRNA)
BackgroundChemotherapy treatment is generally accompanied by adverse effects, which can be significantly reduced using site specific, targeted delivery systems, such as antibody-coated LNPs (immuno-LNPs). However due to inter-and intra-tumor heterogeneity targeting with a single targeting moiety is not sufficient in many cases and in others may induce cancer relapse due to the survival of side […] Read More >
A Novel Nanoparticle that Selectively Delivers RNAi Oligonucelotides to Tumors, Preventing Side Effects to Tissues
UNMET NEEDPancreatic cancer numbers among the most aggressive cancers known today. The overwhelming majority of pancreatic cancer patients pass away within just a year of diagnosis. However, a small minority of patients may live several years with the disease. Our findings pinpoint the inverse correlation between a known oncogene (PLK1) and the expression of an […] Read More >
An Oncolytic Virus That Exploits Immune Defects of Cancer Cells
An oncolytic virus for tumors of different etiology presenting defects in interferon signaling, designed as a potent, specific and safe therapy. Promising in-vivo murine melanoma model shows potential for development as a mono or an add-on to chemotherapy or check-point inhibitors. UNMET NEED On Nov. 2015 the FDA approved the first oncolytic virus based treatment. […] Read More >
Inhibition of the Pax8 Transcription Factor as a Novel Therapeutic Approach for Ovarian and Endometrial Cancer
OUTLINEThe PAX8 transcription factor is essential for ovarian cancer proliferation, and its silencing in ovarian and endometrial cancer cells leads to apoptosis 1,2. PAX8 expression in other tissues is restricted to non-essential organs, suggesting that it is a good target for therapy with minimal side effects 3,4. We propose a novel anti-ovarian and -endometrial cancer […] Read More >
Novel Class of Turn-ON Near-Infrared Probes for Diagnosis and Imaging of Inflammation and Cancer
Complete tumor removal during surgery has a great impact on patient survival. To that end, the surgeon should detect the tumor, remove it and validate that there are no residual cancer cells left behind. Residual cells at the incision margin of the tissue removed during surgery are associated with tumor recurrence and poor prognosis for […] Read More >
A Cytoskeletal Protein Predicts Disease Incidence, Progression, and Prognosis
Brain tumors comprise over one hundred types of masses, differing in location; patient age; molecular, histological, and immunohistochemical characteristics; prognosis and treatment. Glioma tumors originate from neuroglia, cells supporting the brain. Palladin, a structural protein widely expressed in mammalian tissues, has a pivotal role in cytoskeletal dynamics and motility in health and disease. Palladin is […] Read More >
Low Frequency Nanobubbles-Enhanced Ultrasound Mechanotherapy for Noninvasive Cancer Surgery
A unique theranostic ultrasound-based technology for low-energy mechanical ablation of tissues. Noninvasive ultrasound surgery can be achieved using focused ultrasound to locally affect the targeted site without damaging intervening tissues. Mechanical ablation and histotripsy use short and intense acoustic pulses to destroy the tissue via a purely mechanical effect. Here we show that coupled with […] Read More >
Therapeutic Targeting of PD-1/PD-L1 blockade by Novel Small-molecule Inhibitors
Interactions between programmed cell death ligand 1 (PD-L1) and programmed cell death protein 1 (PD-1) lead to the evasion of cancer cells from an efficient immune response. The inhibition of PD-L1/PD-1 has prevented or reversed exhausted T cells, thus enhancing antitumor T-cell responses. In fact, immune checkpoint blockade targeting the PD-1 axis has become one […] Read More >
Leveraging Gene Panel Sequencing Data for Mutational Signature Analysis with Applications to Personalized Treatment
UNMET NEED Mutational signatures and their exposures are key to understanding the processes that shape cancer genomes with applications to diagnosis and treatment. Yet current signature analysis approaches are limited to relatively rich mutation data that comes from whole-genome or whole-exome sequencing. Recently, orders of magnitude sparser data sets from gene panel sequencing have become […] Read More >
